Brand and Other Names:Feraheme
- Classes: Iron Products
Dosing & Uses
Dosage Forms & Strengths
- 510mg/17mL vial (ie, 30mg/mL)
Iron Deficiency Anemia in Chronic Kidney Disease
Should only administer as intravenous infusion in 50-200 mL of 0.9% sterile sodium chloride or 5% sterile dextrose over a minimum period of 15 minutes following dilution
May readminister dose if iron deficiency anemia persists or reoccurs
- Administer dose once blood pressure stable and patient has completed at least 1 hr of hemodialysis
- Monitor for hypotension
- Not removed by hemodialysis; dose adjustment not necessary
MRI of Brain Tumors (Orphan)
For use in MR imaging for the management of brain tumors
Orphan indication sponsor
- Oregon Health & Science University; 3181 SW Sam Jackson Pk Road, Mailcode L603; Portland, OR 97239
Safety and efficacy not established
Frequency Not Defined
Life-threatening anaphylactic/anaphylactoid reactions
Clinically significant hypotension
Loss of consciousness
Ischemic myocardial events
Congestive heart failure
Black Box Warnings
Initial symptoms of hypersensitivity may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest
Fatal and serious hypersensitivity reactions including anaphylaxis have occurred
Initial symptoms may include hypotension, syncope, unresponsiveness, and cardiac/cardiorespiratory arrest
Only administer when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions
Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following infusion, including monitoring of blood pressure and pulse during and after administration
Hypersensitivity reactions have occurred in patients in whom a previous dose was tolerated
Known hypersensitivity to ferumoxytol or any of its components
History of allergic reaction to any intravenous iron product
May cause life-threatening hypersensitivity reactions such as anaphylaxis and/or anaphylactoid reactions (see Black Box Warnings)
Observe for signs and symptoms of hypersensitivity for at least 30 minutes following administration; elderly patients (> 65 years of age) or patients with multiple comorbidities who experience a serious hypersensitivity reaction due to ferumoxytol may have more severe outcomes
Risk of anaphylaxis increases in patients with multiple drug allergies
Anaphylactic reactions presenting with cardiac/cardiorespiratory arrest, syncope, hypotension and unresponsiveness have been identified in post-marketing reports
May cause severe adverse reactions of clinically significant hypotension (monitor blood pressure during/following administration)
Monitor hematologic responses during therapy, do not administer if evidence of iron overload
Can alter magnetic resonance imaging (MRI) studies
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Iron-carbohydrate complex released within macrophage vesicles; either enters intracellular iron storage (eg, ferritin) or transferred to plasma transferrin for transport to erythroid precursor cells for hemoglobin incorporation
Half-Life: 15 hr
Vd: 3.16 L
Peak Plasma Time: 0.32 hr
Peak Plasma Concentration: 206 mcg/mL
Clearance: 69.1 mL/hr
Distribution: Liver, spleen, lymph node, RBC (by 24 hr)
Excretion: Insignificant iron excretion (incorporated into heme)
Dilute dose in 50-200 mL 0.9% NaCl or D5W
Inspect visually for particulate matter and discoloration prior to administration
Should only be administered as a diluted IV infusion over a minimum period of 15 minutes
Administer while the patient is in a reclined or semi-reclined position
Allow at least 30 minutes between administration of ferumoxytol and administration of other medications that could potentially cause serious hypersensitivity reactions and/or hypotension (eg, chemotherapeutic agents, monoclonal antibodies)
Store vials at room temperature (20-25°C [68-77°F]); excursions permitted to 15-30°C (5-86°F)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs